PureTech Health (PRTC) Price & Analysis

Compare

38 Followers

PRTC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.30 - $24.99

Previous CloseN/A

Volume2.03K

Average Volume (3M)2.67K

Market Cap

$436.71M

Enterprise Value$130.14M

Total Cash (Recent Filing)$367.31M

Total Debt (Recent Filing)$22.36M

Price to Earnings (P/E)8.5

Beta0.62

Next Earnings

Apr 23, 2026

EPS Estimate

-1.94

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding24,131,632

10 Day Avg. Volume4,125

30 Day Avg. Volume2,674

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.30

Enterprise Value/Revenue30.16

Enterprise Value/Gross Profit30.16

Enterprise Value/Ebitda3.48

Forecast

1Y Price Target

$19.00

Price Target Upside5.50% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessPositive Ph 2b data underscores the potential for LYT-100 to improve upon standard of care pirfenidone.

New Product LaunchPRTC announced the launch of a new private company, Celea Therapeutics, which will comprise the LYT-100 (deupirfenidone) program.

Regulatory ProgressThe company plans to meet with the FDA to align on a Phase 3 study, indicating forward momentum in the development process.

Bears Say

Investor SentimentInvestor interest in PRTC stock is limited by the expectation that promising assets will get spun out plus the low liquidity for the ADRs.

Stock ValuationPRTC stock continues to trade only modestly above cash levels as investors struggle with low liquidity for the ADRs and valuing the 'hub' of the 'hub-and-spoke' R&D model.

PureTech Health News

PureTech says Vedanta ulcerative colitis study missed endpoint

PureTech Health (PRTC), noted that its Founded Entity, Vedanta Biosciences, announced that its candidate VE202 did not meet...

16d ago

PRTC

PureTech falls 7% to $16.19 after founded entity study miss

12:18 EDT PureTech falls 7% to $16.19 after founded entity study miss Published first on TheFly – the...

16d ago

PRTC

DiaMedica Therapeutics CMO Lorianne Masuoka resigns, Julie Krop succeeds

DiaMedica Therapeutics (DMAC) announced the appointment of Julie Krop as chief medical officer, effective immediately. Krop will succeed...

23d ago

DMAC

PRTC

PureTech Health Reports Strong Progress and Financial Stability

Puretech Health Plc ( ($PRTC) ) has released its Q2 earnings. Here is a breakdown of the information...

28m ago

PRTC

PureTech Health doses first patient in BUOY-1 study

PureTech Health (PRTC) announced that the first patient has been dosed in the Phase 2b BUOY-1 study of...

1M ago

PRTC

PureTech Health CEO Bharatt Chowrira steps down

PureTech Health (PRTC) announced that Bharatt Chowrira has stepped down from his role as CEO and as a...

1M ago

PRTC

PureTech Health says Raju Kucherlapati steps down as board chair

PureTech Health (PRTC) announced that Raju Kucherlapati, PhD, has stepped down from his role as a member and...

2M ago

PRTC

PureTech Health founded entity Vor Bio enters license agreement with RemeGen

PureTech Health (PRTC) noted that its founded entity, Vor Bio (VOR) and RemeGen announced entry into an exclusive...

2M ago

VOR

PRTC

Positive Outlook on PureTech Health Driven by Promising LYT-100 Clinical Trial Results and Strategic Developments

PureTech Health (PRTC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on...

3M ago

PRTC

PureTech Health presents deupirfenidone data at ATS conference

PureTech Health (PRTC) delivered a late-breaking, oral presentation at the 2025 American Thoracic Society international conference in San...

3M ago

PRTC

PureTech Health publishes new research in BMC Pulmonary Medicine

PureTech Health (PRTC) announced the publication of new research in BMC Pulmonary Medicine that provides a view into...

4M ago

PRTC

Optimistic Buy Rating on PureTech Health Driven by Promising LYT-100 Developments and Strategic Growth Plans

Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on PureTech Health (PRTC – Research Report)....

4M ago

PRTC

PureTech Health Reports Strong 2024 Financial Results

Puretech Health Plc ( ($PRTC) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

PRTC

PureTech Health confirms discussions with Nordic Capital Epsilon SCA

The Board of PureTech Health (PRTC) noted the recent press speculation and confirmed that it is in discussions...

5M ago

PRTC

PRTC FAQ

What was Puretech Health Plc’s price range in the past 12 months?

Puretech Health Plc lowest stock price was $13.30 and its highest was $24.99 in the past 12 months.

What is Puretech Health Plc’s market cap?

Puretech Health Plc’s market cap is $436.71M.

When is Puretech Health Plc’s upcoming earnings report date?

Puretech Health Plc’s upcoming earnings report date is Apr 23, 2026 which is in 237 days.

How were Puretech Health Plc’s earnings last quarter?

Puretech Health Plc released its earnings results on Aug 28, 2025. The company reported -$1.9 earnings per share for the quarter, beating the consensus estimate of -$2.04 by $0.14.

Is Puretech Health Plc overvalued?

According to Wall Street analysts Puretech Health Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Puretech Health Plc pay dividends?

Puretech Health Plc does not currently pay dividends.

What is Puretech Health Plc’s EPS estimate?

Puretech Health Plc’s EPS estimate is -1.94.

How many shares outstanding does Puretech Health Plc have?

Puretech Health Plc has 24,131,632 shares outstanding.

What happened to Puretech Health Plc’s price movement after its last earnings report?

Puretech Health Plc reported an EPS of -$1.9 in its last earnings report, beating expectations of -$2.04. Following the earnings report the stock price went down -1.371%.

Which hedge fund is a major shareholder of Puretech Health Plc?

Currently, no hedge funds are holding shares in PRTC

PureTech Health Stock Smart Score

Neutral

Fundamentals

Return on Equity

11.96%

Trailing 12-Months

Asset Growth

-13.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Puretech Health Plc

PureTech Health (PRTC) is a biopharmaceutical company focused on discovering, developing, and commercializing highly differentiated medicines for devastating diseases. The company operates in the healthcare and biotechnology sectors, primarily targeting areas such as immunology, inflammation, and central nervous system disorders. PureTech Health is known for its unique approach, which involves leveraging insights from diverse scientific disciplines to address significant healthcare needs.

PureTech Health (PRTC) Earnings & Revenues

Historic Earnings Reports

PRTC Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant achievements such as successful clinical trial results and FDA approval, alongside challenges like market valuation disconnect and funding requirements for future trials.View all PRTC earnings summaries

PRTC Stock 12 Month Forecast

Average Price Target

$19.00

▲(5.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","27":"$27","18.75":"$18.75","21.5":"$21.5","24.25":"$24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,18.75,21.5,24.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.09,19.083076923076923,19.076153846153847,19.06923076923077,19.06230769230769,19.055384615384614,19.048461538461538,19.04153846153846,19.034615384615385,19.02769230769231,19.02076923076923,19.013846153846153,19.006923076923076,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.09,19.083076923076923,19.076153846153847,19.06923076923077,19.06230769230769,19.055384615384614,19.048461538461538,19.04153846153846,19.034615384615385,19.02769230769231,19.02076923076923,19.013846153846153,19.006923076923076,{"y":19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.09,19.083076923076923,19.076153846153847,19.06923076923077,19.06230769230769,19.055384615384614,19.048461538461538,19.04153846153846,19.034615384615385,19.02769230769231,19.02076923076923,19.013846153846153,19.006923076923076,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.52,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.99,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.46,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >